Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Operating Leases (2019 - 2026)

Nutex Health (NUTX) has disclosed Operating Leases for 8 consecutive years, with $29.6 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Leases fell 2.36% year-over-year to $29.6 million; the TTM value through Mar 2026 reached $29.6 million, down 2.36%, while the annual FY2025 figure was $30.0 million, 1.89% down from the prior year.
  • Operating Leases hit $29.6 million in Q1 2026 for Nutex Health, down from $30.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $30.8 million in Q2 2025 and bottomed at $91238.0 in Q1 2022.
  • Average Operating Leases over 5 years is $20.7 million, with a median of $19.4 million recorded in 2022.
  • On a YoY basis, Operating Leases climbed as much as 28291.31% in 2022 and fell as far as 64.75% in 2022.
  • Nutex Health's Operating Leases stood at $19.4 million in 2022, then decreased by 20.37% to $15.5 million in 2023, then skyrocketed by 97.79% to $30.6 million in 2024, then decreased by 1.89% to $30.0 million in 2025, then fell by 1.35% to $29.6 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $29.6 million, $30.0 million, and $30.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.